Our results indicate that MAP4K4 elevation in lung adenocarcinoma is independent of somatic mutations of KRAS or EGFR. Importantly, we find that MAP4K4 regulation of MAPK/ERK pathway is also independent of KRAS or EGFR mutation status, suggesting that MAP4K4‐targeted therapy could be an effective treatment for a broad range of patients with lung adenocarcinoma. This evidence concerns the gene MAPK1 and lung adenocarcinoma.